1.
N Engl J Med
; 388(6): 565-567, 2023 02 09.
Artículo
en Inglés
| MEDLINE
| ID: mdl-36630611
Asunto(s)
COVID-19 , Inmunogenicidad Vacunal , Humanos , Anticuerpos Neutralizantes , Anticuerpos Antivirales , Vacunas Combinadas/inmunología , Vacunas Combinadas/uso terapéutico , Vacunas Sintéticas/inmunología , Vacunas Sintéticas/uso terapéutico , Inmunogenicidad Vacunal/inmunología , COVID-19/genética , COVID-19/inmunología , COVID-19/prevención & control , COVID-19/virología , Vacunas de ARNm
2.
bioRxiv
; 2022 Oct 25.
Artículo
en Inglés
| MEDLINE
| ID: mdl-36324798
RESUMEN
Waning immunity following mRNA vaccination and the emergence of SARS-CoV-2 variants has led to reduced mRNA vaccine efficacy against both symptomatic infection and severe disease. Bivalent mRNA boosters expressing the Omicron BA.5 and ancestral WA1/2020 Spike proteins have been developed and approved, because BA.5 is currently the dominant SARS-CoV-2 variant and substantially evades neutralizing antibodies (NAbs). Our data show that BA.5 NAb titers were comparable following monovalent and bivalent mRNA boosters.